Loading
A phase 3 trial testing SCTC21C in multiple myeloma, now recruiting.
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant is a phase 3 interventional study registered as NCT07297329, led by Sinocelltech, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant. Planned enrolment is 292 participants (estimated). The study started in 2025-12-29 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Multiple myeloma.